Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP‐lowering therapies, it is expected that effects on IOP will translate into benefits in long‐term patient‐reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12–18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health‐related quality of life, as defined by validated instruments designed to measure that endpoint. HIGHLIGHTSA 30% decrease in rate of visual field progression can be projected to have a significant effect on health‐related quality of life.The US FDA definition of clinically‐meaningful progression corresponds to a slope ≤−0.5 dB/yr in ≥5 abnormal test locations.A 30% decrease in visual field progression with trend analysis is equivalent to a 2–3 mmHg decrease in intraocular pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors associated with lifetime risk of open‐angle glaucoma blindness
Peters, D., Bengtsson, B., & Heijl, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12203 · Cited by 148
Age-related changes in the central visual field for short-wavelength-sensitive pathways
Johnson, C. A., Adams, A. J., Twelker, J. D., & Quigg, J. M. (1988) · Journal of the Optical Society of America A · doi:10.1364/josaa.5.002131 · Cited by 132 · cited 1×
“Johnson et al found that the reduction in sensitivity of short wavelength-sensitive cone pathways (such as those stimulated in SWAP) resulting from aging was greater than that for longer wavelength-sensitive cone pathways(Johnson et al., 1988).”
Cited by
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
Self-citation
Metadata
- Authors
- De Moraes, C. G., Liebmann, J. M., & Levin, L. A.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 56
- Pages
- 107-147
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2538869024
- Cited by
- 203
- References
- 2
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. https://app.cochat.ai/papers/10.1016/j.preteyeres.2016.10.001
- The paper
- De Moraes, C. G., Liebmann, J. M., & Levin, L. A. (2017). Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2016.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.